<DOC>
	<DOCNO>NCT00473135</DOCNO>
	<brief_summary>Dengue fever , cause dengue virus , major health problem tropical subtropical region world . The purpose study evaluate safety immune response 2-dose regimen new monovalent dengue virus vaccine . This study test dengue virus vaccine DEN1delta30 healthy adult .</brief_summary>
	<brief_title>Safety Immune Response 2-dose Regimen rDEN1delta30 Dengue Virus Vaccine</brief_title>
	<detailed_description>Dengue viruses account 50 million case dengue fever one half million case annually dengue hemorrhagic fever/shock syndrome . Dengue virus infection cause illness range mild , self-limited febrile illness life threaten disease . The goal dengue vaccine development induce long-lived antibody response four dengue serotypes . The rDEN1delta30 vaccine live attenuate dengue virus vaccine may protective dengue serotype 1 ( DEN1 ) . The purpose study evaluate safety , reactogenicity , immunogenicity 2-dose regimen rDEN1delta30 dengue virus vaccine . The regimen differ second booster shot vaccine give . This study last 162 day ( 23 week ) participant Cohort 1 , 222 day ( 32 week ) Cohort 2 . Participants Cohort 1 randomly assign receive rDEN1delta30 vaccine placebo Study Day 0 Study Day 120 . Participants Cohort 2 randomly assign receive rDEN1delta30 vaccine placebo Study Day 0 Study Day 180 . There total 25 visit cohort . For cohort , first second vaccination day include physical exam blood urine collection , vital sign measurement , receipt vaccine . A 30 minute observation period follow vaccination . Participants take temperature home three time day first 16 day report diary . At study visit , vital sign measurement , physical exam , blood and/or urine collection occur . At select study visit , participant turn diary card . Some participant may ask join optional skin biopsy substudy .</detailed_description>
	<mesh_term>Dengue</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Good general health Available duration study ( 23 week Cohort 1 32 week Cohort 2 ) Willing use acceptable form contraception duration study Clinically significant neurologic , heart , lung , liver , rheumatologic , autoimmune , kidney disease Behavioral , cognitive , psychiatric disease , opinion investigator , may interfere study Significant laboratory abnormality Medical , work , family problem result alcohol illegal drug use within 12 month prior study entry History severe allergic reaction anaphylaxis Severe asthma HIV1 infect Hepatitis C virus ( HCV ) infect Hepatitis B surface antigen positive Known immunodeficiency syndrome Use corticosteroid immunosuppressive medication within 30 day prior study entry . Individuals use topical nasal corticosteroid exclude . Previous receipt live vaccine within 4 week prior study entry Previous receipt kill vaccine within 2 week prior study entry Absence spleen Previous receipt blood product within 6 month prior study entry Previous receipt dengue virus flavivirus ( e.g. , yellow fever virus , St.Louis encephalitis , West Nile virus ) infection Previous receipt yellow fever dengue vaccine Plans travel area dengue infection common Previous receipt investigational agent within 30 day prior study entry Other condition , opinion investigator , would affect participation study Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Dengue Fever</keyword>
	<keyword>Dengue Vaccine</keyword>
	<keyword>Dengue Virus</keyword>
	<keyword>Dengue Hemorrhagic Fever</keyword>
	<keyword>Dengue Shock Syndrome</keyword>
</DOC>